
Rory D. de Vries

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8529887/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Phenotype and kinetics of SARS-CoV-2–specific T cells in COVID-19 patients with acute respiratory distress syndrome. Science Immunology, 2020, 5, .	5.6	851
2	SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. Science Immunology, 2021, 6, .	5.6	455
3	Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients. Science Immunology, 2022, 7, eabo2202.	5.6	337
4	Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science, 2019, 366, 599-606.	6.0	294
5	Early Target Cells of Measles Virus after Aerosol Infection of Non-Human Primates. PLoS Pathogens, 2011, 7, e1001263.	2.1	181
6	Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets. Science, 2021, 371, 1379-1382.	6.0	158
7	Measles Immune Suppression: Lessons from the Macaque Model. PLoS Pathogens, 2012, 8, e1002885.	2.1	146
8	Acyclovirâ€Resistant Corneal HSVâ€1 Isolates from Patients with Herpetic Keratitis. Journal of Infectious Diseases, 2008, 198, 659-663.	1.9	137
9	The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. Transplantation, 2022, 106, 821-834.	0.5	127
10	Measles Virus Host Invasion and Pathogenesis. Viruses, 2016, 8, 210.	1.5	123
11	Virus-specific T cells as correlate of (cross-)protective immunity against influenza. Vaccine, 2015, 33, 500-506.	1.7	121
12	Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases. Viruses, 2014, 6, 2735-2761.	1.5	106
13	Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming. New England Journal of Medicine, 2022, 386, 951-963.	13.9	102
14	Incomplete genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles. Science Immunology, 2019, 4, .	5.6	98
15	Acyclovir Susceptibility and Genetic Characteristics of Sequential Herpes Simplex Virus Type 1 Corneal Isolates from Patients with Recurrent Herpetic Keratitis. Journal of Infectious Diseases, 2009, 200, 1402-1414.	1.9	95
16	<i>In Vivo</i> Tropism of Attenuated and Pathogenic Measles Virus Expressing Green Fluorescent Protein in Macaques. Journal of Virology, 2010, 84, 4714-4724.	1.5	95
17	The pathogenesis of measles. Current Opinion in Virology, 2012, 2, 248-255.	2.6	90
18	Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct. Science Immunology, 2022, 7, .	5.6	89

#	Article	IF	CITATIONS
19	Human Langerhans cells capture measles virus through Langerin and present viral antigens to CD4 ⁺ T cells but are incapable of crossâ€presentation. European Journal of Immunology, 2011, 41, 2619-2631.	1.6	85
20	Studies into the mechanism of measles-associated immune suppression during a measles outbreak in the Netherlands. Nature Communications, 2018, 9, 4944.	5.8	83
21	DC-SIGN and CD150 Have Distinct Roles in Transmission of Measles Virus from Dendritic Cells to T-Lymphocytes. PLoS Pathogens, 2008, 4, e1000049.	2.1	82
22	Influenza B viruses: not to be discounted. Future Microbiology, 2015, 10, 1447-1465.	1.0	80
23	Morbillivirus Infections: An Introduction. Viruses, 2015, 7, 699-706.	1.5	69
24	Measles Virus Infection of Epithelial Cells in the Macaque Upper Respiratory Tract Is Mediated by Subepithelial Immune Cells. Journal of Virology, 2013, 87, 4033-4042.	1.5	59
25	Matrix-Mâ"¢ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunologic Research, 2018, 66, 224-233.	1.3	58
26	Measles Immune Suppression: Functional Impairment or Numbers Game?. PLoS Pathogens, 2014, 10, e1004482.	2.1	53
27	Live-Attenuated Measles Virus Vaccine Targets Dendritic Cells and Macrophages in Muscle of Nonhuman Primates. Journal of Virology, 2015, 89, 2192-2200.	1.5	53
28	Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection. Vaccine, 2017, 35, 238-247.	1.7	49
29	Seasonal coronavirus–specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19. Journal of Clinical Investigation, 2021, 131, .	3.9	49
30	Recombinant Canine Distemper Virus Strain Snyder Hill Expressing Green or Red Fluorescent Proteins Causes Meningoencephalitis in the Ferret. Journal of Virology, 2012, 86, 7508-7519.	1.5	44
31	Measles Vaccination of Nonhuman Primates Provides Partial Protection against Infection with Canine Distemper Virus. Journal of Virology, 2014, 88, 4423-4433.	1.5	44
32	Viral vector-based influenza vaccines. Human Vaccines and Immunotherapeutics, 2016, 12, 2881-2901.	1.4	44
33	<i>In Vitro</i> Measles Virus Infection of Human Lymphocyte Subsets Demonstrates High Susceptibility and Permissiveness of both Naive and Memory B Cells. Journal of Virology, 2018, 92, .	1.5	43
34	Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head. Vaccines, 2015, 3, 239-262.	2.1	41
35	Human CD8 ⁺ T Cells Damage Noninfected Epithelial Cells during Influenza Virus Infection <i>In Vitro</i> . American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 536-546.	1.4	40
36	Infection of lymphoid tissues in the macaque upper respiratory tract contributes to the emergence of transmissible measles virus. Journal of General Virology, 2013, 94, 1933-1944.	1.3	39

#	Article	IF	CITATIONS
37	Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity. Journal of Allergy and Clinical Immunology, 2022, 149, 1949-1957.	1.5	39
38	Delineating morbillivirus entry, dissemination and airborne transmission by studying in vivo competition of multicolor canine distemper viruses in ferrets. PLoS Pathogens, 2017, 13, e1006371.	2.1	37
39	A Prominent Role for DC-SIGN+ Dendritic Cells in Initiation and Dissemination of Measles Virus Infection in Non-Human Primates. PLoS ONE, 2012, 7, e49573.	1.1	35
40	Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo. Scientific Reports, 2017, 7, 8580.	1.6	34
41	The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant. Nephrology Dialysis Transplantation, 2021, 36, 1761-1764.	0.4	33
42	Needle-free delivery of measles virus vaccine to the lower respiratory tract of non-human primates elicits optimal immunity and protection. Npj Vaccines, 2017, 2, 22.	2.9	32
43	Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk–Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity. Journal of Infectious Diseases, 2018, 217, 3-11.	1.9	31
44	Specific CD8 ⁺ Tâ€lymphocytes control dissemination of measles virus. European Journal of Immunology, 2010, 40, 388-395.	1.6	29
45	Avian Influenza A Virus Pandemic Preparedness and Vaccine Development. Vaccines, 2018, 6, 46.	2.1	29
46	In Vitro Modelling of Respiratory Virus Infections in Human Airway Epithelial Cells – A Systematic Review. Frontiers in Immunology, 2021, 12, 683002.	2.2	28
47	Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test. One Health, 2021, 13, 100313.	1.5	28
48	Universal influenza vaccines, science fiction or soon reality?. Expert Review of Vaccines, 2015, 14, 1299-1301.	2.0	26
49	Paramyxovirus infections in ex vivo lung slice cultures of different host species. Journal of Virological Methods, 2013, 193, 159-165.	1.0	25
50	Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara–Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial. Journal of Infectious Diseases, 2018, 218, 614-623.	1.9	25
51	Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. Clinical Infectious Diseases, 2023, 76, e188-e199.	2.9	24
52	Measles vaccination: new strategies and formulations. Expert Review of Vaccines, 2008, 7, 1215-1223.	2.0	23
53	Animal models of SARS-CoV-2 transmission. Current Opinion in Virology, 2021, 50, 8-16.	2.6	21
54	Measles pathogenesis, immune suppression and animal models. Current Opinion in Virology, 2020, 41, 31-37.	2.6	19

4

#	Article	IF	CITATIONS
55	Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines. Scientific Reports, 2018, 8, 6474.	1.6	18
56	Identification and Characterization of CD4 ⁺ T Cell Epitopes after Shingrix Vaccination. Journal of Virology, 2020, 94, .	1.5	18
57	Induction of Influenza (H5N8) Antibodies by Modified Vaccinia Virus Ankara H5N1 Vaccine. Emerging Infectious Diseases, 2015, 21, 1086-1088.	2.0	16
58	SARS-CoV-2-specific T-cells in unexposed humans: presence of cross-reactive memory cells does not equal protective immunity. Signal Transduction and Targeted Therapy, 2020, 5, 224.	7.1	16
59	Universal influenza vaccines: a realistic option?. Clinical Microbiology and Infection, 2016, 22, S120-S124.	2.8	15
60	High torque tenovirus (TTV) load before first vaccine dose is associated with poor serological response to COVID-19 vaccination in lung transplant recipients. Journal of Heart and Lung Transplantation, 2022, 41, 765-772.	0.3	15
61	Human Respiratory Syncytial Virus Subgroup A and B Infections in Nasal, Bronchial, Small-Airway, and Organoid-Derived Respiratory Cultures. MSphere, 2021, 6, .	1.3	14
62	Understanding the association between sleep, shift work and COVIDâ€19 vaccine immune response efficacy: Protocol of the Sâ€CORE study. Journal of Sleep Research, 2022, 31, e13496.	1.7	14
63	Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol. Frontiers in Immunology, 2021, 12, 753319.	2.2	13
64	Measles skin rash: Infection of lymphoid and myeloid cells in the dermis precedes viral dissemination to the epidermis. PLoS Pathogens, 2020, 16, e1008253.	2.1	13
65	Evaluating measles vaccines: can we assess cellular immunity?. Expert Review of Vaccines, 2012, 11, 779-782.	2.0	11
66	Modeling the measles paradox reveals the importance of cellular immunity in regulating viral clearance. PLoS Pathogens, 2018, 14, e1007493.	2.1	11
67	Difference in sensitivity between SARS-CoV-2–specific T cell assays in patients with underlying conditions. Journal of Clinical Investigation, 2021, 131, .	3.9	11
68	Complete Genome Sequence of Phocine Distemper Virus Isolated from a Harbor Seal (Phoca vitulina) during the 1988 North Sea Epidemic. Genome Announcements, 2013, 1, .	0.8	9
69	Paramyxovirus Infections in Ex Vivo Lung Slice Cultures of Different Host Species. Methods and Protocols, 2018, 1, 12.	0.9	9
70	Sustained Replication of Synthetic Canine Distemper Virus Defective Genomes <i>In Vitro</i> and <i>In Vivo</i> . MSphere, 2021, 6, e0053721.	1.3	9
71	Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern. MBio, 2022, 13, .	1.8	9
72	Evaluation of synthetic infection-enhancing lipopeptides as adjuvants for a live-attenuated canine distemper virus vaccine administered intra-nasally to ferrets. Vaccine, 2012, 30, 5073-5080.	1.7	8

#	Article	IF	CITATIONS
73	Alveolar barrier disruption in varicella pneumonia is associated with neutrophil extracellular trap formation. JCI Insight, 2020, 5, .	2.3	8
74	Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8 ⁺ T Cell Activation <i>In Vitro</i> but Not in C57BL/6 Mice. Journal of Virology, 2016, 90, 10209-10219.	1.5	7
75	Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice. Clinical and Experimental Immunology, 2017, 190, 19-28.	1.1	7
76	Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers. Clinical Infectious Diseases, 2023, 76, e533-e536.	2.9	7
77	Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters. Emerging Microbes and Infections, 2022, 11, 1778-1786.	3.0	7
78	Analysis of the vaccine-induced influenza B virus hemagglutinin-specific antibody dependent cellular cytotoxicity response. Virus Research, 2020, 277, 197839.	1.1	6
79	Modeling Infection and Tropism of Human Parainfluenza Virus Type 3 in Ferrets. MBio, 2022, 13, e0383121.	1.8	5
80	Human Paramyxovirus Infections Induce T Cells That Cross-React with Zoonotic Henipaviruses. MBio, 2020, 11, .	1.8	4
81	In vivo comparison of a laboratory-adapted and clinical-isolate-based recombinant human respiratory syncytial virus. Journal of General Virology, 2020, 101, 1037-1046.	1.3	4
82	Repurposing an In Vitro Measles Virus Dissemination Assay for Screening of Antiviral Compounds. Viruses, 2022, 14, 1186.	1.5	4
83	Absence of COVID-19-associated changes in plasma coagulation proteins and pulmonary thrombosis in the ferret model. Thrombosis Research, 2022, 210, 6-11.	0.8	3
84	Comparable Infection Level and Tropism of Measles Virus and Canine Distemper Virus in Organotypic Brain Slice Cultures Obtained from Natural Host Species. Viruses, 2021, 13, 1582.	1.5	1
85	mSphere of Influence: Understanding Virus-Host Interactions Requires a Multifaceted Approach. MSphere, 2020, 5, .	1.3	Ο
86	Morbillivirus Infections in Non-human Primates: From Humans to Monkeys and Back Again. , 2020, , 205-231.		0